Mineralys Therapeutics Q3 net loss narrows

Mineralys Therapeutics

10/11/2025 21:15

Overview

Mineralys Q3 net loss narrows to $36.9 mln from $56.3 mln in prior year

R&D expenses decreased due to conclusion of lorundrostat pivotal program

Company completed $287.5 mln public equity financing, boosting cash reserves

Outlook

Company has funds to support operations into 2028

Result Drivers

R&D EXPENSES - Decrease in R&D expenses due to conclusion of lorundrostat pivotal program

CASH POSITION - Completion of $287.5 mln public equity financing strengthened cash reserves

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.52
Q3 Net Income
-$36.93 mln
Q3 Operating Expenses
$41.13 mln
Q3 Operating Income
-$41.13 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Mineralys Therapeutics Inc is $46.50, about 18.2% above its November 7 closing price of $38.02

Press Release: ID:nGNX7bYDBY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)